The data indicates a consistent decline in the sales of cardiovascular system medicines in Japan from 2024 to 2028, as projected by the forecast. The market stood at an estimated $8.27 billion (PPP) in 2024 and is expected to decrease steadily each year, reaching $7.58 billion (PPP) by 2028. This represents an annual decreasing trend with year-on-year variations showing slight declines. Given a lack of increase or stabilization in sales figures, this trend suggests a shrinking market size for cardiovascular medicines over the five-year period.

Future trends to watch for include:

Changes in government healthcare policies affecting pricing or reimbursement structures.
Technological advancements or new product launches within cardiovascular treatments.
Demographic factors, such as an aging population, which may influence demand.